window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 2 clinical trial

  • Biologics & Biosimilars,Clinical Trials,Manufacturing,Oncology,Research & Development

    Anixa Biosciences advances breast cancer vaccine toward Phase 2 with Cytovance manufacturing deal

    Anixa Biosciences is advancing its breast cancer vaccine programme towards [...]

    April 7, 2026
  • Clinical Development,Drug Delivery & Formulation,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    AmacaThera named Life Sciences Ontario emerging company of the year

    AmacaThera has been named Emerging Company of the Year by [...]

    February 13, 2026
  • Biotech,Clinical Development,Clinical Trials,Infectious Diseases,Vaccines

    NeoVac reports Phase 1 and Phase 2 data for NeomiVac mRNA LNP covid-19 vaccine

    NeoVac has reported positive first-in-human Phase 1 and Phase 2 [...]

    February 6, 2026
  • Clinical Development,Clinical Trials,Rare Diseases,Respiratory

    Cereno Scientific broadens CS014 development focus to pulmonary hypertension linked to interstitial lung disease

    Cereno Scientific has broadened the clinical development focus of its [...]

    February 5, 2026
  • Uncategorised

    MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study

    MaaT Pharma has randomized the first patient in the IMMUNOLIFE [...]

    January 21, 2026
  • Biotech,Cell & Gene Therapy,Clinical Development,Clinical Trials,Opthalmology,Rare Diseases,Research & Development

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    January 16, 2026
  • Clinical Trials,Neurosciences,Oncology,Pharmaceuticals and therapeutics

    MediciNova completes patient enrollment in Phase 2 neuropathy prevention study

    MediciNova has completed patient enrollment in a Phase 2 clinical [...]

    December 19, 2025
  • Biologics & Biosimilars,Biotech,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Technology and platforms

    AmacaThera signs exclusive global licensing agreement with Pacira Biosciences for up to $230 million

    AmacaThera has entered an exclusive worldwide licensing agreement with Pacira [...]

    November 4, 2025
  • Biologics & Biosimilars,Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Levicept to present Phase 2 LEVI-04 data showing bone marrow lesion and pain reduction at ACR Convergence 2025

    Levicept Ltd will present new findings from its Phase 2 [...]

    October 2, 2025
  • Biologics & Biosimilars,Clinical Trials,Pharmaceuticals and therapeutics

    Acella Pharmaceuticals reports positive Phase 2 results for North Star desiccated thyroid extract

    Acella Pharmaceuticals and Neuvosyn Laboratories have reported positive topline results [...]

    September 24, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top